Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 12, 2024.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The neuroimmunologist at Clínica Alemana de Santiago and head of the University Center for Multiple Sclerosis at Ramos Mejía Hospital discussed Latin American efforts to understand neuromyelitis optica spectrum disorder during the COVID-19 pandemic. [WATCH TIME: 5 minutes]
The professor in the department of neurology with McGovern Medical School at UTHealth Houston talked about findings from a recent study that investigated T cell specificity in the spinal fluid of patients with multiple sclerosis. [WATCH TIME: 10 minutes]
In episode 4 of the "Are You Recognizing CIDP? Changing the Course With Evolving Treatment Strategies" video series, Richard Lewis, MD, professor of neurology at Cedars-Sinai Medical Center, reviews the red flag symptoms of CIPD that should prompt a referral your patient.
In this week's NeuroVoices Q&A, the associate director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine provided commentary on positive phase 1 findings assessing ALX-001, a highly selective agent in development for neurodegenerative diseases.
In this episode of the "Paradigm Shift in Parkinson’s Disease Diagnosis" video series, neurology experts discuss the importance of early and accurate diagnosis of Parkinson’s disease, the role of alpha-synuclein in the diagnosis of synucleinopathies and approaches to implementing screening protocols in clinical practice.